SAN DIEGO, CALIFORNIA, U.S.A., 6 SEPTEMBER 2016 – Diazyme Laboratories announces that it will continue to distribute its procalcitonin (PCT) test in Germany through its German subsidiary Diazyme Europe. This follows the lifting by the district court of Munich on August 31, 2016 of a preliminary injunction obtained by B.R.A.H.M.S. GmbH (BRAHMS) on July 13, 2016 based on alleged infringement of BRAHMS's European PCT patent EP 2 028 493 B1.
PCT is a marker for diagnosis of sepsis, and the Diazyme PCT test is specifically developed for uses on general chemistry analyzers.
In 2015, BRAHMS filed a lawsuit in Germany against Diazyme Europe along with other litigation, alleging infringement of BRAHMS's PCT patent EP 0 880 702 B1. Diazyme Europe then filed a nullity action in the Federal Patent Court in Munich. On July 26, 2016, the Court revoked the German part of EP 0 880 702 B1 in its entirety.
In connection with these ongoing legal actions with BRAHMS, the Managing Director of Diazyme Laboratories, Dr. Chong Yuan, says, "The legal actions by BRAHMS are without merit. Diazyme will continue to vigorously defend its user-friendly and cost-effective PCT tests."
Diazyme Laboratories is a division of General Atomics headquartered in La Jolla, California. Diazyme uses its enzyme and antibody platform technologies to develop innovative assays for clinical and research uses with reduced costs and improved performance. Its products include diagnostic blood tests for cardiovascular disease, diabetes, nutritional assessment, liver disease, renal disease and electrolytes. Information regarding Diazyme's enzyme technology and related products can be found on its website at www.diazyme.com.
For Further Information Contact:
Dr. Abhijit Datta, Ph.D